Navigation Links
Immunosyn Corporation to Present at FSX
Date:10/24/2007

LA JOLLA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Immunosyn Corporation's (OTC Bulletin Board: IMYN) CEO, Stephen Ferrone, will make a presentation to brokers and financial institutions at the Financial Services Exchange (FSX) Investment Conference at the Pointe South Mountain Resort in Phoenix, AZ on Thursday, October 25, 2007.

Immunosyn has obtained exclusive worldwide marketing, sales and distribution rights to SF-1019 from its largest shareholder, Argyll Biotechnologies, LLC. Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. The company went public in January of this year and its stock will begin trading on Friday, October 26, 2007.

"Immunosyn is privileged to present to the elite group of brokers and dealers at FSX. We look forward to communicating our company's objectives and overview as well as to answering questions," noted Ferrone.

FSX is a premier investment conference organization attended by independent NASD broker/dealer firms. For more than 20 years, FSX has brought these firms together for the purpose of sharing information and showcasing investment opportunities.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.

FOR FURTHER INFORMATION, CONTACT: Bill Kraus/Lisa Baker/Devon Blaine

The Blaine Group

310/360-1499

310/360-1498 (FAX)

blaine@blainegroupinc.com


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Wisconsin firms to present at Cleantech venture capital event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Participants ... and a high-performance fume hood. Along with the advantages and disadvantages of ductless, ... vs. ducted hoods in the laboratory. , Attendees will learn from an industry ...
(Date:9/19/2017)... ... , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured ... Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in 2003 and ... in the potential of stem cell therapy and a fast friendship was formed. , Dr. ...
(Date:9/19/2017)... ... September 19, 2017 , ... One of the biggest ... eliminated, said Lyle Probst, President, CEO and Founder of ExcitePCR ™. ... pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, ...
(Date:9/19/2017)... Ann Arbor, MI (PRWEB) , ... September 19, ... ... chemical testing laboratory, is pleased to announce the recipients of its 2017 Science ... academic achievement, exceptional leadership qualities, and involvement with community service defray the costs ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
Breaking Biology News(10 mins):